Literature DB >> 14974863

Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma.

Billie-Rose Cameron1, Kenneth W Berean.   

Abstract

OBJECTIVE: The follicular variant of papillary thyroid carcinoma (FV-PTC) may be difficult to differentiate from other thyroid neoplasms with follicular architecture such as follicular adenoma, follicular carcinoma, and dominant nodules in nodular goitre. Obvious differences in treatment and expected outcome between these lesions mandate that the distinction between them be made accurately. To decrease the subjectivity of this differential diagnosis, we undertook this study to determine if any difference in cytokeratin profile exists between FV-PTC and other follicular lesions of the thyroid gland.
DESIGN: Immunohistochemical analysis based on a retrospective pathology review.
SETTING: Vancouver General Hospital, Vancouver, BC.
METHODS: The files of the Vancouver General Hospital anatomic pathology laboratory were searched for cases of typical papillary thyroid carcinoma (PTC), FV-PTC, follicular adenoma, follicular carcinoma, and nodular goitre. The slides and reports were reviewed, and those cases with confirmed diagnosis and adequate tissue were selected for inclusion in the study. Monoclonal antibodies to cytokeratin 19 (CK19), 20 (CK20), and 7 (CK7) were applied to formalin-fixed, paraffin-embedded tissue sections.
RESULTS: All cases of PTC, including FV-PTC, as well as all follicular adenomas, follicular carcinomas, and nodular goitres, stained positively for CK7 and, except for a single follicular carcinoma, were negative for CK20. CK19 decorated almost all PTCs, including FV-PTC, although the staining was sometimes focal. The majority of the cases of follicular adenoma, follicular carcinoma, and nodular goitre were negative or showed focal staining with CK19, although occasional cases showed diffuse positivity.
CONCLUSIONS: CK19 strongly stains the majority of PTC, including FV-PTC, in a diffuse manner. However, overlap with the staining seen in other follicular lesions limits its utility in a routine diagnostic setting.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14974863     DOI: 10.2310/7070.2003.11429

Source DB:  PubMed          Journal:  J Otolaryngol        ISSN: 0381-6605


  5 in total

1.  Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas.

Authors:  Yoon-La Choi; Mi Kyung Kim; Jin-Won Suh; Joungho Han; Jung Han Kim; Jung Hyun Yang; Seok Jin Nam
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

2.  Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma.

Authors:  Lei Gong; Ping Chen; Xianjun Liu; Ying Han; Yanping Zhou; Weidong Zhang; Hong Li; Chuanjia Li; Jiang Xie
Journal:  Gland Surg       Date:  2012-05

3.  CK19 IS A USEFUL MARKER IN DISTINGUISHING FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA FROM BENIGN THYROID LESIONS WITH FOLLICULAR GROWTH PATTERN.

Authors:  F Noroozinia; A Gheibi; B Ilkhanizadeh; A Abbasi
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Oct-Dec       Impact factor: 0.877

4.  Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis.

Authors:  J E Barroeta; Z W Baloch; P Lal; T L Pasha; P J Zhang; V A LiVolsi
Journal:  Endocr Pathol       Date:  2006       Impact factor: 4.056

Review 5.  Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis.

Authors:  Leandro Luongo de Matos; Adriana Braz Del Giglio; Carolina Ogawa Matsubayashi; Michelle de Lima Farah; Auro Del Giglio; Maria Aparecida da Silva Pinhal
Journal:  Diagn Pathol       Date:  2012-08-13       Impact factor: 2.644

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.